Race Oncology (ASX: RAC) reveals breakthrough chemotherapy heart protection discovery for Zantrene®

Описание к видео Race Oncology (ASX: RAC) reveals breakthrough chemotherapy heart protection discovery for Zantrene®

Race Oncology CEO Phil Lynch and CSO Dr Daniel Tillett discuss breakthrough new research that has found their drug Zantrene® is able to protect heart muscle cells from anthracycline (specifically doxorubicin) induced cell death while improving the killing of breast cancer cells.

Комментарии

Информация по комментариям в разработке

Похожие видео